G

ood morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and invigorating, because that familiar routine of relentless meetings, deadlines, and the like has returned. You knew this would happen, though, yes? Well, what can you do, except to reach for a much-needed cup or three of stimulation? Our flavor today is cinnamon, for those keeping track. Please do join us. After all, the neurons need all the help they can get. Meanwhile, here are some tidbits. Hope you have a smashing day and, of course, do keep in touch …

Shire won an injunction in a German court against Roche for making incomplete and misleading remarks about one of its medicines, a new turn in a closely watched battle between the two drug makers, Reuters reports. In a Roche clinical trial, some patients who experienced bleeding despite getting its experimental emicizumab drug were treated with so-called bypassing agents. Shire contends Roche disparaged its FEIBA bypassing agent.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Hi Ed. To paraphrase the late radio man Paul Harvey, here’s the rest of the story on the objection to Dr Fitzgerald. Linked below is the board for the International Menopause Society. Most of them are in the tank for Big Pharma, and Big Pharma makes branded “anti aging” products like the estrogens. On the other hand Fitzgerald supports compounding these products, which saves the patient a ton of money. “And now you know the rest of the story”.

    http://www.imsociety.org/editorial_board.php

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.